Synapsoft logo
AI Insights from Disclosures
Searching...
Quratis Inc. 348080
Searching...

Company Summary

Quarterly Performance Revenue Operating Margin

Market Sentiment

※ Click the graph to view AI analysis information for that month.
Revenue
Consolidated
Separate
Operating Income
Consolidated
Separate
Net Income
Consolidated
Separate

Financials

Excel

No financial data is available for this period.
~
Quarterly
Annual
No data is available for this period.

*Values beyond the fourth decimal place of the unit are displayed as '0/-0'

Financial Indicator Forecast

※ These forecasts are simple AI estimates based on historical data and may differ from actual results.

Company Overview

as of June 2026
Quratis Inc. is developing QTP101, a tuberculosis prevention vaccine for adults and adolescents, QTP105, a schistosomiasis prevention vaccine, and QTP104, a next-generation mRNA COVID-19 prevention vaccine, based on its 'vaccine development platform technology.' This 'vaccine development platform technology' refers to technology that unifies and enables the company to independently carry out the entire new drug development process, from the search for and discovery of vaccine candidate substances through research and development, process development, clinical development, and product approval, to securing production technology and distribution networks for final commercialization, and the company is focusing on new drug development based on this technology.
Representative Director Kim Seongjun
Founded July 15, 2016
Corporation Type KOSDAQ
Industry Classification Research and experimental development on medical sciences and pharmacy
Corporate number 11011-6122983
Business number 402-86-14683
Phone Number 070-4141-5942
Fax Number 02-867-0125
Website quratis.com
Company Address 143 Uiryodanji-gil, Osong-eup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do
Products & Services

Financial Health

Executives

Employees

Shareholders

Industry revenue

Disclosures

Comments

0 / 255

AI Assistant